Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Catalyst Pharmaceuticals Inc (CPRX)

375 + Investors. Track Smart Money conviction in CPRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +7
Streak
2Q ▲
Buyers last Q
54%

Smart Money Signals — CPRX

Based on 377 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added CPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
377 hedge funds hold CPRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +5% more funds vs a year ago

fund count last 6Q
+19 new funds entered over the past year (+5% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 54% buying

201 buying172 selling
Last quarter: 201 funds bought or added vs 172 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-13 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 48 → 51 → 69 → 56. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 25% medium ■ 23% new
196 out of 377 hedge funds have held CPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

72 → 48 → 51 → 69 → 56 new funds/Q
New funds entering each quarter: 48 → 51 → 69 → 56. A growing number of institutions are discovering CPRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Deep conviction — 58% of holders stayed 2+ years

■ 58% veterans ■ 13% 1-2yr ■ 29% new
Of 385 current holders: 224 (58%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 40% AUM from top-100 funds

40% from top-100 AUM funds
53 of 377 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in CPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CPRX

In 2026 Q1, 201 hedge funds were net buyers of CPRX (56 opened a new position, 145 added to an existing one), while 172 reduced or exited (123 trimmed, 49 sold completely) — a 54% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. 40% of total institutional value in CPRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +7 funds (more new holders than closures). Total institutional holders: 377.

Hedge Fund Ownership: CPRX

How many hedge funds hold CPRX — quarterly history vs. share price
Quarterly hedge fund ownership of CPRX vs. share price

Market Analysis: CPRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CPRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Catalyst Pharmaceuticals Inc (CPRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CPRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 76d ago
CPRX
+26.7%
XLV
+4.9%

CPRX outperformed XLV by +21.8% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 31d ago
CPRX
+0.6%
XLV
+6.0%

Since the filing became public, CPRX outperformed XLV by -5.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

29 top-rated funds 2 high-conviction
Consensus
6.4
/ 10
breadth
×
Elite
3.4
/ 10
conviction
Hedge Fund Positioning: CPRX
375 + Investors

Track Smart Money conviction in CPRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 375 370 1.35%
13F Shares 104M 104M -0.37%
Total Value $2.49B $2.40B 4.02%
New Positions 55 69 -14
Increased Positions 145 119 +26
Closed Positions 50 53 -3
Reduced Positions 118 127 -9
Total Calls 4 2 100.0%
Total Puts 4 2 100.0%
PUT/CALL Ratio 1.0 1.0 Neutral

Statistics: CPRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

375 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CPRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CPRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Gables Capital Management INC. 4.45% 424,581 $10.5M
2 JW Asset Management, LLC 3.95% 388,392 $9.6M
3 Ishara Investments LP 1.92% 82,000 $2.0M
4 Knott David M Jr 1.77% 120,000 $3.0M
5 Globeflex Capital L P 1.69% 450,580 $11.2M
6 Sidoxia Capital Management, LLC 1.52% 71,316 $1.8M
7 Advisors Preferred, LLC 1.39% 381,183 $9.4M
8 Deerfield Management Company, L.P. 1.15% 3,943,600 $97.6M
9 Bridge City Capital, LLC 1.07% 155,689 $3.9M
10 Third Avenue Management LLC 0.84% 210,161 $5.2M
11 Future Fund LLC 0.82% 94,727 $2.3M
12 Clark Estates Inc/Ny 0.68% 113,918 $2.8M
13 Kennedy Capital Management LLC 0.63% 1,199,598 $29.7M
14 Zinnia Wealth Advisory, LLC 0.61% 22,147 $548K
15 Juncture Wealth Strategies, LLC 0.59% 71,809 $1.8M
16 AlphaCentric Advisors LLC 0.58% 23,286 $577K
17 Oberweis Asset Management Inc/ 0.57% 780,570 $19.3M
18 Royce & Associates LP 0.51% 2,089,906 $51.7M
19 Stanley-Laman Group, Ltd. 0.47% 155,021 $3.8M
20 Renaissance Group LLC 0.46% 445,215 $11.0M
21 Hussman Strategic Advisors, INC. 0.45% 84,000 $2.1M
22 Systematic Financial Management LP 0.42% 747,515 $18.5M
23 Linden Thomas Advisory Services, LLC 0.39% 163,591 $4.1M
24 Chase Investment Counsel Corp 0.39% 60,000 $1.5M
25 Oliver Luxxe Assets LLC 0.36% 96,636 $2.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Catalyst Pharmaceuticals Inc (CPRX)

What does the Smart Money Trend signal show for CPRX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added CPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CPRX?

Slight buying edge — 54% buying: Last quarter: 201 funds bought or added vs 172 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CPRX holders?

Elite ownership — 40% AUM from top-100 funds: 53 of 377 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in CPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CPRX?

52% of holders stayed for 2+ years: 196 out of 377 hedge funds have held CPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Catalyst Pharmaceuticals Inc (CPRX) following the 2026 Q1 hedge fund 13F filings?

As of today, CPRX has moved +0.6% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -5.4%. Since the quarter end (March 31, 2026), CPRX has gained +26.7% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →